Table of Contents Author Guidelines Submit a Manuscript
International Journal of Otolaryngology
Volume 2014 (2014), Article ID 682439, 6 pages
http://dx.doi.org/10.1155/2014/682439
Clinical Study

Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

1Faculty of Neurology, Bohomolets National Medical University, Shevchenko Avenue, 13, Kiev 01601, Ukraine
2Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Willmar-Schwabe-Straße 4, 76227 Karlsruhe, Germany
3Institute of Neurology, Psychiatry and Narcology of the NAMS of Ukraine SI, 46, Akademika Pavlova Street, Kharkiv 61068, Ukraine

Received 5 March 2014; Accepted 30 May 2014; Published 25 June 2014

Academic Editor: Michael D. Seidman

Copyright © 2014 Larysa Sokolova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per day) or betahistine (32 mg per day) for 12 weeks. An 11-point numeric analogue scale, the Vertigo Symptom Scale—short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures. Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment. There was no significant intergroup difference with regard to changes in any outcome measure. Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales. Clinical global impression was rated “very much improved” or “much improved” in 79% of patients treated with EGb 761 and in 70% receiving betahistine. With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients. In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated. This trial is registered with controlled-trials.com ISRCTN02262139.